Claims
- 1. A method of treating viral infections comprising administering to a patient in need thereof a therapeutically effective amount of (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadizol)-3-yl urea derivative having the formula:
- 2. A method of treating viral infections according to claim 1 wherein the virus is selected from the group consisting of HIV, herpes simplex, hepatitis and Kaposi's sarcoma.
- 3. A method according to claim 2 wherein said viral infection is hepatitis C or hepatitis B.
- 4. A method according to claim 3 wherein said viral infection is HIV.
- 5. A method of treating HIV, herpes simplex or hepatitis according to claim 2 comprising administering a therapeutically effective amount of a pharmaceutical composition comprising (5-phenyl-1,2,4-thiadiazol)-3-yl thiourea or the pharmaceutical addition salt thereof or the prodrugs thereof.
- 6. A method according to claim 5 wherein said method comprises administering to a patient in need thereof from about 1 mg/kg body weight to about 10000 mg/kg body weight of said (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative.
- 7. A method according to claim 1 wherein said treatment comprises administering a combination therapy with said (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadizol)-3-yl urea derivative.
- 8. A method according to claim 7 wherein said combination therapy administration of a member selected from the group consisting of AZT, TC-3, protease inhibitors, cyclovir, famciclovir, valacyclovir, Ribavirin, interferon, combinations of Ribavirin, and Interferon, beta globulin and a recombinant alpha interferon
- 9. A method according to claim 1 wherein said (5-aryl-1,2,4-thiadiazol)-3-yl thiourea is administered in a solid form and wherein said solid form includes a carrier selected from the group consisting of lactose, sucrose, gelatin and agar.
- 10. A method according to claim 9 wherein from about 10 mg/kg body weight to about 6000 mg/kg body weight of said (5-aryl-1,2,4-thiadiazol)-3-yl thiourea is administered.
- 11. A method according to claim 10 wherein said (5-aryl-1,2,4-thiadiazol)-3-yl thiourea is administered in a liquid form and wherein said liquid dosage form is selected from the group consisting of aqueous solutions, alcohol solutions, emulsions, suspensions, and suspensions reconstituted from non-effervescent and effervescent preparations and suspensions in pharmaceutically acceptable fats or oils.
- 12. A method of treating viral infections comprising administering a therapeutically effective amount of (5-phenyl-1,2,4-thiadiazol)-3-yl thiourea having the formula:
- 13. A method according to claim 12 wherein R1 is hydrogen and n is 4 and R is hydrogen.
- 14. A method of treating viral infections according to claim 13 wherein the virus is selected from the group consisting of herpes simplex, hepatitis and Kaposi's sarcoma.
- 15. A method of treating hepatitis C comprising administering a therapeutically effective amount of a pharmaceutical composition comprising (5-phenyl-1,2,4-thiadiazol)-3-yl thiourea or the pharmaceutical addition salt thereof.
- 16. A method according to claim 15 wherein said pharmaceutical composition comprises from about 1 mg/kg to about 6000 mg/kg of said (5-aryl-1,2,4-thiadiazol)-3-yl thiourea.
- 17. A method according to claim 16 wherein said method further administration of a combination therapy wherein said combination therapy comprises administration of a member selected from the group consisting of cyclovir, famciclovir or valacyclovir, Ribavirin, interferon or combinations of Ribavirin and Interferon or beta globulin or mixtures thereof.
- 18. A method of treating herpes simplex comprising administering a therapeutically effective amount of a pharmaceutical composition comprising (5-phenyl-1,2,4-thiadiazol)-3-yl thiourea or a pharmaceutical addition salt thereof.
- 19. A method of treating fungal infections comprising administering a therapeutically effective amount of composition having the formula:
- 20. A method of treating fungal infections according to claim 20 wherein said pharmaceutical composition comprises (5-aryl-1,2,4-thiadiazol)-3-yl thiourea or the pharmaceutical addition salt thereof.
- 21. A method of treating bovine diarrhea virus comprising administering a therapeutically effective amount of composition having the formula:
- 22. A pharmaceutical composition for treating viral infections comprising a therapeutically effective amount of (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadizol)-3-yl urea derivative having the formula:
- 23. A pharmaceutical composition according to claim 23 comprising a pharmaceutically acceptable carrier and from about 1 mg to about 6000 mg of (5-aryl-1,2,4-thiadiazol)-3-yl thiourea or its pharmaceutical addition salt
- 24. A pharmaceutical composition according to claim 24 wherein said pharmaceutical acceptable acid addition salt are selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates. maleates, malates, citrates, benzoates, salicylates, ascorbates and mixtures thereof.
- 25. A pharmaceutical composition according to claim 25 comprising from about 150 mg to about 5000 mg of said (5-aryl-1,2,4-thiadiazol)-3-yl thiourea.
- 26. A pharmaceutical composition according to claim 24 wherein said composition further comprises a pharmaceutical carrier.
- 27. A pharmaceutical composition according to claim 27 which is in a solid form comprising a carrier selected from the group consisting of lactose, sucrose, gelatin and agar.
- 28. A pharmaceutical composition according to claim 28 in a liquid form wherein said liquid dosage form is selected from the group consisting of aqueous solutions, emulsions, suspension solutions, and suspensions reconstituted from non-effervescent and effervescent preparations.
- 29. A pharmaceutical composition according to claim 29 wherein said liquid dosage form further comprises a member selected from the group consisting of suspending agents, diluents, sweeteners, flavorants, colorants, preservatives, emulsifying agents and coloring agents, and mixtures thereof.
- 30. A method of treating HIV according to claim 1 comprising administering a therapeutically effective amount of a pharmaceutical composition comprising (5-phenyl-1,2,4-thiadiazol)-3-yl thiourea or a pharmaceutical addition salt thereof.
- 31. A method of treating herpes simplex according to claim 1 comprising administering a therapeutically effective amount of a pharmaceutical composition comprising (5-phenyl-1,2,4-thiadiazol)-3-yl thiourea or a pharmaceutical addition salt thereof.
- 32. A method of treating hepatitis C according to claim 1 comprising administering a therapeutically effective amount of a pharmaceutical composition comprising (5-phenyl-1,2,4-thiadiazol)-3-yl thiourea or a pharmaceutical addition salts thereof.
Parent Case Info
[0001] This application is a continuation in part of application of J. B. Camden, Ser. No. 09/281,896 filed Mar. 31, 1999.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09535172 |
Mar 2000 |
US |
Child |
09812094 |
Mar 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09281896 |
Mar 1999 |
US |
Child |
09535172 |
Mar 2000 |
US |